Particularly, R98S has been described as a mutation hotspot with >90% of RPL10 mutations at this residue, accounting for ~8% of pediatric T-ALL.204,205 The mutants including I33V, E66G, I70M and I70L in RPL10 have been reported in multiple myeloma with low frequency (2%) and cluster in a region that is distinct from the mutation hotspot identified in T-ALL.206 An increase in RPL10 expression has been observed in ovarian and pancreatic cancers and linked to enhanced cell proliferation, invasion, survival, and resistance to oxidative stress.207,208. The gene discussed is RPL10; the disease is familial pancreatic carcinoma.